INTERCEPT PHARMACEUTICALS IN (ICPT)
US45845P1084 - Common Stock
| MRQ (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 102.74M | 50.52M | 84.71M | 58.20M | 70.10M | |||
| Marketable Securities | 219.98M | 435.05M | 334.98M | 411.50M | 582.60M | |||
| Receivables | 32.48M | 26.86M | 28.34M | 41.50M | 38.00M | |||
| Other Current Assets | 28.25M | 27.70M | 59.99M | 34.50M | 30.60M | |||
| Total Current Assets | 383.44M | 540.13M | 508.02M | 545.70M | 721.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 5.79M | 6.11M | 6.84M | 18.70M | 18.40M | |||
| Other Non-Current Assets | 3.92M | 7.47M | 12.17M | 16.10M | 15.10M | |||
| Total Non-Current Assets | 9.72M | 13.58M | 19.00M | 34.80M | 33.60M | |||
| TOTAL ASSETS | 393.16M | 553.71M | 527.02M | 580.50M | 754.90M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 109.57M | N/A | N/A | N/A | |||
| Accrued Expenses | 38.98M | 42.73M | 41.07M | 83.10M | 62.50M | |||
| Accounts Payable | 10.27M | 14.23M | 17.60M | 24.60M | 19.00M | |||
| Other Current Liabilities | 41.60M | 63.55M | 109.49M | 71.40M | 80.50M | |||
| Total Current Liabilities | 90.84M | 230.08M | 168.16M | 179.10M | 162.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 223.86M | 223.10M | 539.78M | 560.60M | 532.10M | |||
| Other Non-Current Liabilities | 6.62M | 7.45M | 3.04M | 7.70M | 9.20M | |||
| Total Non-Current Liabilities | 230.47M | 230.56M | 542.82M | 568.20M | 541.30M | |||
| TOTAL LIABILITIES | 321.32M | 460.63M | 710.99M | 747.30M | 703.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.18B | -2.14B | -2.49B | -2.40B | -2.12B | |||
| Additional Paid In Capital | 2.26B | 2.24B | 2.31B | 2.23B | 2.18B | |||
| Common Shares | 42.00K | 42.00K | 30.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -7.20M | -8.26M | -2.87M | -2.50M | -1.10M | |||
| Shares Outstanding | 41.81M | 41.52M | 29.57M | 33.00M | 32.90M | |||
| Tangible Book Value per Share | 1.72 | 2.24 | -6.22 | -5.06 | 1.57 | |||
| Total Shareholders' Equity | 71.84M | 93.08M | -183.96M | -166.90M | 51.60M | |||
| TOTAL LIABILITIES AND EQUITY | 393.16M | 553.71M | 527.02M | 580.50M | 754.90M | |||
| Statistics | ||||||||
| Debt/Equity | 3.12 | 2.40 | -2.93 | -3.36 | 10.31 | |||
| Current Ratio | 4.22 | 2.35 | 3.02 | 3.05 | 4.45 | |||
| Return On Assets (ROA) | -15.67% | 40.06% | -17.35% | -47.36% | -45.66% | |||
| Return On Equity (ROE) | -85.76% | 238.31% | N/A | N/A | -668.02% | |||
All data in USD